The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets

Infectious Agents and Cancer

Rosario Pivonello²  Annamaria Colao²  Francesco Izzo³  Federica Cariati²  Gaia Cuomo¹  Mariarosaria Negri²  Maria Cristina De Martino²  Claudia Pivonello² 

[1] IRCCS Fondazione SDN, Naples, Italy;Dipartimento di Medicina Clinica e Chirurgia, Università Federico II di Napoli, Via Sergio Pansini, 5, Naples 80131, Italy;National Cancer Institute G Pascale Foundation, Naples, Italy

关键词: Hepatocarcinoma;    Hepatocarcinogenesis;    Normal liver;    Somatostatin receptors;    Somatostatin;    GH-IGF1 axis;   

Others  :  1161164
DOI  :  10.1186/1750-9378-9-27

 received in 2012-11-14, accepted in 2014-06-23,  发布年份 2014

【 摘 要 】

Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide. Different signalling pathways have been identified to be implicated in the pathogenesis of HCC; among these, GH, IGF and somatostatin (SST) pathways have emerged as some of the major pathways implicated in the development of HCC. Physiologically, GH-IGF-SST system plays a crucial role in liver growth and development since GH induces IGF1 and IGF2 secretion and the expression of their receptors, involved in hepatocytes cell proliferation, differentiation and metabolism. On the other hand, somatostatin receptors (SSTRs) are exclusively present on the biliary tract. Importantly, the GH-IGF-SST system components have been indicated as regulators of hepatocarcinogenesis. Reduction of GH binding affinity to GH receptor, decreased serum IGF1 and increased serum IGF2 production, overexpression of IGF1 receptor, loss of function of IGF2 receptor and appearance of SSTRs are frequently observed in human HCC. In particular, recently, many studies have evaluated the correlation between increased levels of IGF1 receptors and liver diseases and the oncogenic role of IGF2 and its involvement in angiogenesis, migration and, consequently, in tumour progression. SST directly or indirectly influences tumour growth and development through the inhibition of cell proliferation and secretion and induction of apoptosis, even though SST role in hepatocarcinogenesis is still opened to argument.

This review addresses the present evidences suggesting a role of the GH-IGF-SST system in the development and progression of HCC, and describes the therapeutic perspectives, based on the targeting of GH-IGF-SST system, which have been hypothesised and experimented in HCC.

【 授权许可】

   
2014 Pivonello et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]The European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC): EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012, 48(5):599-641.
• [2]Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27(9):1485-1491.
• [3]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [4]Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999, 19(3):329-338.
• [5]Villanueva A, Hernandez-Gea V, Llovet JM: Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013, 10(1):34-42.
• [6]Severi T, van Malenstein H, Verslype C, van Pelt JF: Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol Sin 2010, 31(11):1409-1420.
• [7]Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC: Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002, 181–182:43-47.
• [8]Merle P, Trepo C: Molecular mechanisms underlying hepatocellular carcinoma. Viruses 2009, 1(3):852-872.
• [9]Libbrecht L, Desmet V, Roskams T: Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005, 25(1):16-27.
• [10]Wong CM, Ng IO: Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008, 28(2):160-174.
• [11]Durr R, Caselmann WH: Carcinogenesis of primary liver malignancies. Langenbecks Arch Surg 2000, 385(3):154-161.
• [12]Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007, 27(1):55-76.
• [13]Jain S, Singhal S, Lee P, Xu R: Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2010, 2(1):105-118.
• [14]Sia D, Villanueva A: Signaling pathways in hepatocellular carcinoma. Oncology 2011, 81(Suppl 1):18-23.
• [15]Whittaker S, Marais R, Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29(36):4989-5005.
• [16]Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, Van De Rijn M, Botstein D, Brown PO: Gene expression patterns in human liver cancers. Mol Biol Cell 2002, 13(6):1929-1939.
• [17]Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clement B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouze E, Calvo F, Zucman-Rossi J: Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012, 44(6):694-698.
• [18]Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45(1):42-52.
• [19]Renaville R, Hammadi M, Portetelle D: Role of the somatotropic axis in the mammalian metabolism. Domest Anim Endocrinol 2002, 23(1–2):351-360.
• [20]Gourmelen M, Perin L, Le Bouc Y: IGFs and their binding proteins. Nucl Med Biol 1994, 21(3):297-302.
• [21]Mair M, Blaas L, Osterreicher CH, Casanova E, Eferl R: JAK-STAT signaling in hepatic fibrosis. Front Biosci 2011, 16:2794-2811.
• [22]Laban C, Bustin SA, Jenkins PJ: The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 2003, 14(1):28-34.
• [23]Rudd MF, Webb EL, Matakidou A, Sellick GS, Williams RD, Bridle H, Eisen T, Houlston RS, Consortium G: Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006, 16(6):693-701.
• [24]Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004, 68(6):1003-1015.
• [25]De Martino MC, Hofland LJ, Lamberts SW: Somatostatin and somatostatin receptors: from basic concepts to clinical applications. Prog Brain Res 2010, 182:255-280.
• [26]Hasskarl J, Kaufmann M, Schmid HA: Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol 2011, 7(7):895-913.
• [27]Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A: Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004, 53(8):1180-1189.
• [28]Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA: Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci 2008, 53(9):2359-2365.
• [29]Moller N, Jorgensen JO: Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009, 30(2):152-177.
• [30]Herrington J, Smit LS, Schwartz J, Carter-Su C: The role of STAT proteins in growth hormone signaling. Oncogene 2000, 19(21):2585-2597.
• [31]Eleswarapu S, Gu Z, Jiang H: Growth hormone regulation of insulin-like growth factor-I gene expression may be mediated by multiple distal signal transducer and activator of transcription 5 binding sites. Endocrinology 2008, 149(5):2230-2240.
• [32]Schneider HJ, Pagotto U, Stalla GK: Central effects of the somatotropic system. Eur J Endocrinol 2003, 149(5):377-392.
• [33]Tannenbaum GS, Somatostatin EJ: Hormonal Control of Growth, vol. V. In Handbook of Physiology edn Edited by Kostyo JL, Goodman HM. 1999.
• [34]Lanning NJ, Carter-Su C: Recent advances in growth hormone signaling. Rev Endocr Metab Disord 2006, 7(4):225-235.
• [35]Woelfle J, Rotwein P: In vivo regulation of growth hormone-stimulated gene transcription by STAT5b. Am J Physiol Endocrinol Metab 2004, 286(3):E393-E401.
• [36]Waxman DJ, O'Connor C: Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol 2006, 20(11):2613-2629.
• [37]Baumann G: Growth hormone binding protein 2001. J Pediatr Endocrinol Metab 2001, 14(4):355-375.
• [38]von Horn H, Ekstrom C, Ellis E, Olivecrona H, Einarsson C, Tally M, Ekstrom TJ: GH is a regulator of IGF2 promoter-specific transcription in human liver. J Endocrinol 2002, 172(3):457-465.
• [39]Forbes K, Westwood M: The IGF axis and placental function. a mini review. Horm Res 2008, 69(3):129-137.
• [40]Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R: Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009, 30(6):586-623.
• [41]Harris LK, Westwood M: Biology and significance of signalling pathways activated by IGF-II. Growth Factors 2012, 30(1):1-12.
• [42]Scott CD, Firth SM: The role of the M6P/IGF-II receptor in cancer: tumor suppression or garbage disposal? Horm Metab Res 2004, 36(5):261-271.
• [43]Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8(12):915-928.
• [44]Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, Vigneri R: The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008, 114(1):23-37.
• [45]Clemmons DR: Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997, 8(1):45-62.
• [46]Rajaram S, Baylink DJ, Mohan S: Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997, 18(6):801-831.
• [47]Clemmons DR: Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998, 140(1–2):19-24.
• [48]Mohan S, Baylink DJ: IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 2002, 175(1):19-31.
• [49]Alvaro D, Metalli VD, Alpini G, Onori P, Franchitto A, Barbaro B, Glaser SS, Francis H, Cantafora A, Blotta I, Attili AF, Gaudio E: The intrahepatic biliary epithelium is a target of the growth hormone/insulin-like growth factor 1 axis. J Hepatol 2005, 43(5):875-883.
• [50]Takahashi Y: Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver [Review]. Endocr J 2012.
• [51]Scott CD, Martin JL, Baxter RC: Production of insulin-like growth factor I and its binding protein by adult rat hepatocytes in primary culture. Endocrinology 1985, 116(3):1094-1101.
• [52]Goodyer CG, Figueiredo RM, Krackovitch S, De Souza LL, Manalo JA, Zogopoulos G: Characterization of the growth hormone receptor in human dermal fibroblasts and liver during development. Am J Physiol Endocrinol Metab 2001, 281(6):E1213-E1220.
• [53]Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A: The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A 2008, 105(49):19378-19383.
• [54]Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 1999, 96(12):7088-7092.
• [55]Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D: Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A 1999, 96(13):7324-7329.
• [56]Lamas E, Zindy F, Seurin D, Guguen-Guillouzo C, Brechot C: Expression of insulin-like growth factor II and receptors for insulin-like growth factor II, insulin-like growth factor I and insulin in isolated and cultured rat hepatocytes. Hepatology 1991, 13(5):936-940.
• [57]Zindy F, Lamas E, Schmidt S, Kirn A, Brechot C: Expression of insulin-like growth factor II (IGF-II) and IGF-II, IGF-I and insulin receptors mRNAs in isolated non-parenchymal rat liver cells. J Hepatol 1992, 14(1):30-34.
• [58]Li X, Cui H, Sandstedt B, Nordlinder H, Larsson E, Ekstrom TJ: Expression levels of the insulin-like growth factor-II gene (IGF2) in the human liver: developmental relationships of the four promoters. J Endocrinol 1996, 149(1):117-124.
• [59]Ekstrom TJ, Cui H, Li X, Ohlsson R: Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development 1995, 121(2):309-316.
• [60]Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK: Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 1988, 81(4):976-981.
• [61]Villafuerte BC, Goldstein S, Murphy LJ, Phillips LS: Nutrition and somatomedin. XXV. Regulation of insulinlike growth factor binding protein 1 in primary cultures of normal rat hepatocytes. Diabetes 1991, 40(7):837-841.
• [62]Boni-Schnetzler M, Schmid C, Mary JL, Zimmerli B, Meier PJ, Zapf J, Schwander J, Froesch ER: Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes. Mol Endocrinol 1990, 4(9):1320-1326.
• [63]Menuelle P, Binoux M, Plas C: Regulation by insulin-like growth factor (IGF) binding proteins of IGF-II-stimulated glycogenesis in cultured fetal rat hepatocytes. Endocrinology 1995, 136(12):5305-5310.
• [64]Scharf JG, Knittel T, Dombrowski F, Muller L, Saile B, Braulke T, Hartmann H, Ramadori G: Characterization of the IGF axis components in isolated rat hepatic stellate cells. Hepatology 1998, 27(5):1275-1284.
• [65]Scharf JG, Braulke T, Hartmann H, Ramadori G: Regulation of the components of the 150 kDa IGF binding protein complex in cocultures of rat hepatocytes and Kupffer cells by 3',5'-cyclic adenosine monophosphate. J Cell Physiol 2001, 186(3):425-436.
• [66]Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ: Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994, 79(6):1871-1876.
• [67]Gentilini A, Feliers D, Pinzani M, Woodruff K, Abboud S: Characterization and regulation of insulin-like growth factor binding proteins in human hepatic stellate cells. J Cell Physiol 1998, 174(2):240-250.
• [68]Scharf J, Ramadori G, Braulke T, Hartmann H: Synthesis of insulinlike growth factor binding proteins and of the acid-labile subunit in primary cultures of rat hepatocytes, of Kupffer cells, and in cocultures: regulation by insulin, insulinlike growth factor, and growth hormone. Hepatology 1996, 23(4):818-827.
• [69]Pao CI, Farmer PK, Begovic S, Villafuerte BC, Wu GJ, Robertson DG, Phillips LS: Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein 1 gene transcription by hormones and provision of amino acids in rat hepatocytes. Mol Endocrinol 1993, 7(12):1561-1568.
• [70]Liu HL, Huo L, Wang L: Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells. Acta Pharmacol Sin 2004, 25(10):1380-1386.
• [71]Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, Brandau W, Mann K, Antoch G, Bockisch A, Petersenn S: 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging 2011, 38(7):1224-1236.
• [72]Tietz PS, Alpini G, Pham LD, Larusso NF: Somatostatin inhibits secretin-induced ductal hypercholeresis and exocytosis by cholangiocytes. Am J Physiol 1995, 269(1 Pt 1):G110-G118.
• [73]Catalan RE, Martinez AM, Araones MD: Evidence for a role of somatostatin in lipid metabolism of liver and adipose tissue. Regul Pept 1984, 8(2):147-159.
• [74]Li S, Hou G, Wang Y, Su X, Xue L: Influence of recombinant human growth hormone (rhGH) on proliferation of hepatocellular carcinoma cells with positive and negative growth hormone receptors in vitro. Tumori 2010, 96(2):282-288.
• [75]Ferbeyre G, Moriggl R: The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta 2011, 1815(1):104-114.
• [76]Yu JH, Zhu BM, Wickre M, Riedlinger G, Chen W, Hosui A, Robinson GW, Hennighausen L: The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B negatively regulate cell proliferation through the activation of cyclin-dependent kinase inhibitor 2b (Cdkn2b) and Cdkn1a expression. Hepatology 2010, 52(5):1808-1818.
• [77]Lee TK, Man K, Poon RT, Lo CM, Yuen AP, Ng IO, Ng KT, Leonard W, Fan ST: Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res 2006, 66(20):9948-9956.
• [78]Hosui A, Kimura A, Yamaji D, Zhu BM, Na R, Hennighausen L: Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med 2009, 206(4):819-831.
• [79]Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H, Hasselblatt P, Schlederer M, Haindl S, Wagner KU, Engblom D, Haemmerle G, Kratky D, Sexl V, Kenner L, Kozlov AV, Terracciano L, Zechner R, Schuetz G, Casanova E, Pospisilik JA, Heim MH, Moriggl R: Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 2011, 54(4):1398-1409.
• [80]Garcia-Caballero T, Mertani HM, Lambert A, Gallego R, Fraga M, Pintos E, Forteza J, Chevallier M, Lobie PE, Vonderhaar BK, Beiras A, Morel G: Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas. Endocrine 2000, 12(3):265-271.
• [81]Wang HT, Wang J, Ou QJ, Liu XP, Chen S: [Expression of growth hormone receptor mRNA in hepatocellular carcinoma and matched para-cancer cirrhotic liver tissue]. Ai Zheng 2002, 21(2):146-148.
• [82]Liu JP, Wang HT, Ou QJ, Lu YT, Lu HP, Gao JH, Chu ZH, Zhao HY: [Expression of growth hormone receptor in hepatocellular carcinoma and its significance]. Ai Zheng 2003, 22(3):298-301.
• [83]Cao J, Luo SM, Liang L, Lai J: Effects of parenteral nutrition without and with growth hormone on growth hormone/insulin-like growth factor-1 axis after hepatectomy in hepatocellular carcinoma with liver cirrhosis. JPEN J Parenter Enteral Nutr 2007, 31(6):496-501.
• [84]Shankar TP, Fredi JL, Himmelstein S, Solomon SS, Duckworth WC: Elevated growth hormone levels and insulin resistance in patients with cirrhosis of the liver. Am J Med Sci 1986, 291(4):248-254.
• [85]Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P: Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol 1993, 88(10):1744-1748.
• [86]Assy N, Pruzansky Y, Gaitini D, Shen Orr Z, Hochberg Z, Baruch Y: Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol 2008, 49(1):34-42.
• [87]Pivonello CNM, De Martino MC, de Angelis C, Napolitano M, Izzo F, Colao C, Hofland LJ, Pivonello R: Targeting the insulin-like growth factor 1 (IGF1R) and insulin (IR) receptors with a dual IGF1R/IR inhibitor, OSI-906, to potentiate mTOR inhibitor effects in experimental models of hepatocellular carcinoma (HCC). In European Congress of Endocrinology. Wroclaw, Poland; 2014.
• [88]Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoel MJ, Fartoux L, Venot C, Bladt F, Housset C, Rosmorduc O: Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 2009, 15(17):5445-5456.
• [89]Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, Zeng Z, Wang Q, Li T, Hoffman AR: A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 2003, 111(2):265-273.
• [90]Hung TM, Ho CM, Liu YC, Lee JL, Liao YR, Wu YM, Ho MC, Chen CH, Lai HS, Lee PH: Up-Regulation of MicroRNA-190b Plays a Role for Decreased IGF-1 That Induces Insulin Resistance in Human Hepatocellular Carcinoma. Plos One 2014., 9(2)
• [91]Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL: Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006, 80(5):2418-2428.
• [92]Maillard P, Walic M, Meuleman P, Roohvand F, Huby T, Le Goff W, Leroux-Roels G, Pecheur EI, Budkowska A: Lipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entry. Plos One 2011, 6(10):e26637.
• [93]Sukhanov SVC, Higashi Y, Titterington J, Delafontaine P: Insulin-like growth factor I (IGF-1) downregulates lipoprotein lipase and suppresses atherosclerotic foam cell formation in vivo and in vitro. Faseb J 2009, Meeting Abstract Supplement(23):593.591.
• [94]Lin SB, Hsieh SH, Hsu HL, Lai MY, Kan LS, Au LC: Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. J Biochem 1997, 122(4):717-722.
• [95]Ma N, Li F, Li D, Hui Y, Wang X, Qiao Y, Zhang Y, Xiang Y, Zhou J, Zhou L, Zheng X, Gao X: Igf2-derived intronic miR-483 promotes mouse hepatocellular carcinoma cell proliferation. Mol Cell Biochem 2012, 361(1–2):337-343.
• [96]Yao N, Yao D, Wang L, Dong Z, Wu W, Qiu L, Yan X, Yu D, Chen J, Sai W, Zhang H, Yang J: Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2012, 33(5):1767-1776.
• [97]Zinevich LS, Mikaelyan AS: Igf1 expression in mouse model of liver carcinogenesis. Dokl Biochem Biophys 2012, 442:1-3.
• [98]Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA, Varmus HE: The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 2005, 25(4):1228-1237.
• [99]Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M: Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004, 363(9418):1346-1353.
• [100]Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, Lamberts SW, Monti D, Bucci L, Cevenini E, Cavagnini F, Franceschi C, Hofland LJ, Mari D, Janssen J: Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (Albany NY) 2012, 4(9):580-589.
• [101]Mattera D, Capuano G, Colao A, Pivonello R, Manguso F, Puzziello A, D'Agostino L: Increased IGF-I : IGFBP-3 ratio in patients with hepatocellular carcinoma. Clin Endocrinol (Oxf) 2003, 59(6):699-706.
• [102]Nikolic JA, Todorovic V, Bozic M, Tosic L, Bulajic M, Alempijevic T, Nedic O, Masnikosa R: Serum insulin-like growth factor (IGF)-II is more closely associated with liver dysfunction than is IGF-I in patients with cirrhosis. Clin Chim Acta 2000, 294(1–2):169-177.
• [103]Stuver SO, Kuper H, Tzonou A, Lagiou P, Spanos E, Hsieh CC, Mantzoros C, Trichopoulos D: Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer 2000, 87(1):118-121.
• [104]Colakoglu O, Taskiran B, Colakoglu G, Kizildag S, Ari Ozcan F, Unsal B: Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis. Turk J Gastroenterol 2007, 18(4):245-249.
• [105]Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL: Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011, 29(29):3892-3899.
• [106]Janssen JA: Insulin-like growth factor I: pros and cons of a bioassay. Horm Res Paediatr 2011, 76(Suppl 1):106-110.
• [107]Rehem RNAMA, El-Shikh WMHM: Serum IGF-1, IGF-2 and IGFBP-3 as Parameters in the Assessment of Liver Dysfunction in Patients with Hepatic Cirrhosis and in the Diagnosis of Hepatocellular Carcinoma. Hepatogastroenterology 2011, 58(107):949-954.
• [108]Morace C, Cucunato M, Bellerone R, De Caro G, Crino S, Fortiguerra A, Spadaro F, Zirilli A, Alibrandi A, Consolo P, Luigiano C, Resta ML, Ferrau O, Spadaro A: Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma? Eur J Intern Med 2012, 23(6):e157-e161.
• [109]Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, Jiang DR, Zhu JH, Meng XY: Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol 2005, 11(30):4655-4660.
• [110]Su TS, Liu WY, Han SH, Jansen M, Yang-Fen TL, P'Eng FK, Chou CK: Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 1989, 49(7):1773-1777.
• [111]Stefano JT, Correa-Giannella ML, Ribeiro CM, Alves VA, Massarollo PC, Machado MC, Giannella-Neto D: Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol 2006, 12(24):3821-3828.
• [112]Luo SM, Tan WM, Deng WX, Zhuang SM, Luo JW: Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol 2005, 11(27):4272-4276.
• [113]Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D, Czech MP, Ullrich A, Brechot C: Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988, 48(23):6844-6849.
• [114]Sohda T, Yun K, Iwata K, Soejima H, Okumura M: Increased expression of insulin-like growth factor 2 in hepatocellular carcinoma is primarily regulated at the transcriptional level. Lab Invest 1996, 75(3):307-311.
• [115]Su Q, Liu YF, Zhang JF, Zhang SX, Li DF, Yang JJ: Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 1994, 20(4 Pt 1):788-799.
• [116]Sedlaczek N, Hasilik A, Neuhaus P, Schuppan D, Herbst H: Focal overexpression of insulin-like growth factor 2 by hepatocytes and cholangiocytes in viral liver cirrhosis. Br J Cancer 2003, 88(5):733-739.
• [117]d'Arville CN, Nouri-Aria KT, Johnson P, Williams R: Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology 1991, 13(2):310-315.
• [118]Nardone G, Romano M, Calabro A, Pedone PV, de Sio I, Persico M, Budillon G, Bruni CB, Riccio A, Zarrilli R: Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology 1996, 23(6):1304-1312.
• [119]Li X, Nong Z, Ekstrom C, Larsson E, Nordlinder H, Hofmann WJ, Trautwein C, Odenthal M, Dienes HP, Ekstrom TJ, Schirmacher P: Disrupted IGF2 promoter control by silencing of promoter P1 in human hepatocellular carcinoma. Cancer Res 1997, 57(10):2048-2054.
• [120]Uchida K, Kondo M, Takeda S, Osada H, Takahashi T, Nakao A: Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol Carcinog 1997, 18(4):193-198.
• [121]Tang SH, Hu W, Hu JJ, Wu SL, Li JF, Luo YH, Cao MR, Zhou HK, Jiang XW: Hepatitis B virus X protein promotes P3 transcript expression of the insulin-like growth factor 2 (IGF2) gene via inducing hypomethylation of P3 promoter in hepatocellular carcinoma. Liver Int 2014.
• [122]Lee S, Park U, Lee YI: Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites. Virology 2001, 283(2):167-177.
• [123]Lee YI, Lee S, Das GC, Park US, Park SM: Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma. Oncogene 2000, 19(33):3717-3726.
• [124]Lee SH, Chung YH, Kim JA, Lee D, Jin YJ, Shim JH, Jang MK, Cho EY, Shin ES, Lee JE, Park NH, Yu E, Lee YJ: Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma. Liver Int 2012, 32(3):457-466.
• [125]Tsai TF, Yauk YK, Chou CK, Ting LP, Chang C, Hu CP, Han SH, Su TS: Evidence of autocrine regulation in human hepatoma cell lines. Biochem Biophys Res Commun 1988, 153(1):39-45.
• [126]Verspohl EJ, Maddux BA, Goldfine ID: Insulin and insulin-like growth factor I regulate the same biological functions in HEP-G2 cells via their own specific receptors. J Clin Endocrinol Metab 1988, 67(1):169-174.
• [127]Nussbaum T, Samarin J, Ehemann V, Bissinger M, Ryschich E, Khamidjanov A, Yu X, Gretz N, Schirmacher P, Breuhahn K: Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis. Hepatology 2008, 48(1):146-156.
• [128]Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, Thung S, Moyano S, Toffanin S, Minguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010, 52(4):550-559.
• [129]Lee YI, Han YJ, Lee SY, Park SK, Park YJ, Moon HB, Shin JH, Lee JH: Activation of insulin-like growth factor II signaling by mutant type p53: physiological implications for potentiation of IGF-II signaling by p53 mutant 249. Mol Cell Endocrinol 2003, 203(1–2):51-63.
• [130]Kim SO, Park JG, Lee YI: Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 1996, 56(16):3831-3836.
• [131]Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, Wong N: MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012, 33(6):1134-1141.
• [132]Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49(5):1571-1582.
• [133]Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009, 284(46):32015-32027.
• [134]Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM: A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010, 52(5):1702-1712.
• [135]Tomizawa M, Saisho H: Insulin-like growth factor (IGF)-II regulates CCAAT/enhancer binding protein alpha expression via phosphatidyl-inositol 3 kinase in human hepatoblastoma cell lines. J Cell Biochem 2007, 102(1):161-170.
• [136]Dong ZZ, Yao M, Qian J, Yan XD, Chen J, Yan MJ, Yao NH, Yao DF: [Abnormal expression of insulin-like growth factor-II and intervening of its mRNA transcription in the promotion of HepG2 cell apoptosis]. Zhonghua Yi Xue Za Zhi 2013, 93(12):892-896.
• [137]Sue SR, Chari RS, Kong FM, Mills JJ, Fine RL, Jirtle RL, Meyers WC: Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma. Ann Surg 1995, 222(2):171-178.
• [138]De Souza AT, Hankins GR, Washington MK, Fine RL, Orton TC, Jirtle RL: Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995, 10(9):1725-1729.
• [139]De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL: M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995, 11(4):447-449.
• [140]De Souza AT, Yamada T, Mills JJ, Jirtle RL: Imprinted genes in liver carcinogenesis. FASEB J 1997, 11(1):60-67.
• [141]Donaghy AJ, Delhanty PJ, Ho KK, Williams R, Baxter RC: Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol 2002, 36(6):751-758.
• [142]Baruch Y, Amit T, Hertz P, Enat R, Youdim MB, Hochberg Z: Decreased serum growth hormone-binding protein in patients with liver cirrhosis. J Clin Endocrinol Metab 1991, 73(4):777-780.
• [143]Fusco A, Miele L, D'Uonnolo A, Forgione A, Riccardi L, Cefalo C, Barini A, Bianchi A, Giampietro A, Cimino V, Landolfi R, Grieco A, De Marinis L: Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels. Clin Endocrinol (Oxf) 2012, 77(4):531-536.
• [144]Dastot F, Sobrier ML, Duquesnoy P, Duriez B, Goossens M, Amselem S: Alternatively spliced forms in the cytoplasmic domain of the human growth hormone (GH) receptor regulate its ability to generate a soluble GH-binding protein. Proc Natl Acad Sci U S A 1996, 93(20):10723-10728.
• [145]Dastot F, Duquesnoy P, Sobrier ML, Goossens M, Amselem S: Evolutionary divergence of the truncated growth hormone receptor isoform in its ability to generate a soluble growth hormone binding protein. Mol Cell Endocrinol 1998, 137(1):79-84.
• [146]Ross RJ, Esposito N, Shen XY, Von Laue S, Chew SL, Dobson PR, Postel-Vinay MC, Finidori J: A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein. Mol Endocrinol 1997, 11(3):265-273.
• [147]Shen XY, Holt RI, Miell JP, Justice S, Portmann B, Postel-Vinay MC, Ross RJ: Cirrhotic liver expresses low levels of the full-length and truncated growth hormone receptors. J Clin Endocrinol Metab 1998, 83(7):2532-2538.
• [148]Nam SY, Kim KR, Song YD, Lim SK, Lee HC, Huh KB: GH-binding protein in obese men with varying glucose tolerance: relationship to body fat distribution, insulin secretion and the GH-IGF-I axis. Eur J Endocrinol 1999, 140(2):159-163.
• [149]Fang P, Hwa V, Rosenfeld R: IGFBPs and cancer. Novartis Found Symp 2004, 262:215-230. discussion 230–214, 265–218
• [150]Aishima S, Basaki Y, Oda Y, Kuroda Y, Nishihara Y, Taguchi K, Taketomi A, Maehara Y, Hosoi F, Maruyama Y, Fotovati A, Oie S, Ono M, Ueno T, Sata M, Yano H, Kojiro M, Kuwano M, Tsuneyoshi M: High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci 2006, 97(11):1182-1190.
• [151]Huynh H, Chow PK, Ooi LL, Soo KC: A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002, 13(3):115-122.
• [152]Yumoto E, Nakatsukasa H, Hanafusa T, Yumoto Y, Nouso K, Matsumoto E, Onishi T, Takuma Y, Tanaka H, Fujikawa T, Suzuki M, Uemura M, Shiratori Y: IGFBP-3 expression in hepatocellular carcinoma involves abnormalities in TGF-beta and/or Rb signaling pathways. Int J Oncol 2005, 27(5):1223-1230.
• [153]Gong Y, Cui L, Minuk GY: The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol Cell Biochem 2000, 207(1–2):101-104.
• [154]Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, Yumoto E, Higashi T, Tsuji T: Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 2002, 176(2):149-158.
• [155]Notas G, Kolios G, Mastrodimou N, Kampa M, Vasilaki A, Xidakis C, Castanas E, Thermos K, Kouroumalis E: Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors. J Hepatol 2004, 40(5):792-798.
• [156]Hua YP, Yin XY, Peng BG, Li SQ, Lai JM, Liang HZ, Liang LJ: Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy 2009, 55(5):312-320.
• [157]Lasfer M, Vadrot N, Schally AV, Nagy A, Halmos G, Pessayre D, Feldmann G, Reyl-Desmars FJ: Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. J Hepatol 2005, 42(2):230-237.
• [158]Pivonello C, Vitale G, Izzo F, Di Sarno A, Giorgio A, Hofland LJ, Colao A, Pivonello R: Hepatocellular carcinoma (HCC) as a neuroendocrine tumor: a preliminar molecular study [abstract]. Endocrine Abstracts 2012, 781.
• [159]Abdel-Hamid NM, Mohafez OM, Zakaria S, Thabet K: Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 2014, 35(3):2497-2502.
• [160]Verhoef C, van Dekken H, Hofland LJ, Zondervan PE, de Wilt JH, van Marion R, de Man RA, IJzermans JN, van Eijck CH: Somatostatin receptor in human hepatocellular carcinomas: biological, patient and tumor characteristics. Dig Surg 2008, 25(1):21-26.
• [161]Li S, Liu Y, Shen Z: Characterization of Somatostatin Receptor 2 and 5 Expression in Operable Hepatocellular Carcinomas. Hepatogastroenterology 2012., 59(119)
• [162]Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V, Australasian Gastro-Intestinal Trials Group Ag HI: Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 2006, 95(7):853-861.
• [163]D'Agostino L, Manguso F, Pivonello R, Colao A: The role of somatostatin analogs in the management of hepatocellular carcinoma. J Endocrinol Invest 2003, 26(8 Suppl):131-133.
• [164]Blaker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Broring DC, Pace A, Greten H, De Weerth A: Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004, 41(1):112-118.
• [165]Nguyen-Khac E, Ollivier I, Aparicio T, Moullart V, Hugentobler A, Lebtahi R, Lobry C, Susini C, Duhamel C, Hommel S, Cadranel JF, Joly JP, Barbare JC, Tramier B, Dupas JL: Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study. Cancer Biol Ther 2009, 8(21):2033-2039.
• [166]Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E: Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol 2007, 13(23):3164-3170.
• [167]Yao M, Wang L, Yan M, Yan X, Yao D: Insulin-Like Growth Factor-II: Molecular-Targeted Therapy for Hepatocellular Carcinoma. 2013. [chapter 13]
• [168]Wu J, Zhu AX: Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 2011, 4:30.
• [169]Imai K, Takaoka A: Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006, 6(9):714-727.
• [170]Goetsch L, Corvaia N: Insulin-like growth factor receptor type I as a target for cancer therapy. Immunotherapy 2009, 1(2):265-279.
• [171]Pradhananga S, Wilkinson I, Ross RJ: Pegvisomant: structure and function. J Mol Endocrinol 2002, 29(1):11-14.
• [172]Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, Schiff R, Osborne CK, Lee AV: The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006, 98(3):315-327.
• [173]Dagnaes-Hansen F, Duan H, Rasmussen LM, Friend KE, Flyvbjerg A: Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res 2004, 24(6):3735-3742.
• [174]McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE: Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001, 94(3):487-492.
• [175]Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS: Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res 2011, 71(3):1029-1040.
• [176]Alami N, Page V, Yu Q, Jerome L, Paterson J, Shiry L, Leyland-Jones B: Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 2008, 18(6):487-496.
• [177]Arnaldez FI, Helman LJ: Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 2012, 26(3):527-542.
• [178]Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007, 13(18 Pt 2):5549s-5555s.
• [179]Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL: A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003, 63(24):8912-8921.
• [180]Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW: Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 2008, 60(2):166-174.
• [181]Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN: Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 2006, 12(15):4755-4765.
• [182]Allen GAE, Modhia F, Ludwig D, Hicklin D, Harari P: Inhibition of insulin-like growth factor-1 receptor signaling impairs proliferation of head and neck, lung, prostate and breast cancer cells [Abstract]. Proc Amer Assoc Cancer Res 2005., 46
• [183]Wu KZL, Zhang K, Burtrum D, Ludwig DL, Moore MAS: A humanized insulin-like growth factor I receptor antibody inhibits multiple myeloma cell growth in vivo through anti-angiogenesis [Abstract]. Proc Am Assoc Cancer Res 2005., 46
• [184]Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB: A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 2014, 60(2):319-324.
• [185]Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS: Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009, 1(6):1153-1171.
• [186]Zhao H, Desai V, Wang J, Epstein DM, Miglarese M, Buck E: Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines. Mol Cancer Ther 2012, 11(2):503-513.
• [187]Laursen T, Jorgensen JO, Christiansen JS: The management of adult growth hormone deficiency syndrome. Expert Opin Pharmacother 2008, 9(14):2435-2450.
• [188]Li RS, Pourpak A, Morris SW: Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach. J Med Chem 2009, 52(16):4981-5004.
• [189]Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146(5):707-716.
• [190]Theodoropoulou M, Stalla GK: Somatostatin receptors: From signaling to clinical practice. Front Neuroendocrinol 2013, 34(3):228-252.
• [191]Florio T: Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008, 13:822-840.
• [192]Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F: The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 2009, 42(5):361-370.
• [193]Susini C, Buscail L: Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006, 17(12):1733-1742.
• [194]Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB: Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 2008, 15(3):701-720.
• [195]Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M, Harder J, Arnold C, Gress T, Arnold R: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009, 27(28):4656-4663.
• [196]Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA: Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011, 17(3):313-321.
• [197]Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, Wang J, Li JS, Zhai ZM, Xue Q: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2003, 129(6):327-334.
• [198]Engel JB, Schally AV, Halmos G, Baker B, Nagy A, Keller G: Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 2005, 104(6):1312-1321.
• [199]Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csernus V, Kovacs M, Koppan M, Szepeshazi K, Kahan Z: Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A 1998, 95(4):1794-1799.
• [200]Xie Y, Chen S, Wang CH, Tang CW: SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts. Cancer Biol Ther 2011, 12(1):86-92.
• [201]Chen S, Xie Y, Wang CH, Tang CW: [Effects of octreotide on necrosis of hepatocellular carcinoma xenografts in nude mice]. Ai Zheng 2009, 28(7):673-678.
• [202]Xie Y, Chen S, Wang CH, Tang CW: [Induction of necrosis in the hepatocellular carcinoma HepG2 xenografts treated with SOM230]. Zhonghua Gan Zang Bing Za Zhi 2009, 17(10):759-764.
• [203]Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J: Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000, 268(2):567-571.
• [204]Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201–995). Clin Cancer Res 1997, 3(2):265-272.
• [205]Watson JC, Balster DA, Gebhardt BM, O'Dorisio TM, O'Dorisio MS, Espenan GD, Drouant GJ, Woltering EA: Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001, 85(2):266-272.
• [206]Borbath I, Leclercq IA, Sempoux C, Abarca-Quinones J, Desaeger C, Horsmans Y: Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Chem Biol Interact 2010, 183(1):238-248.
• [207]Raderer M, Hejna MH, Kurtaran A, Kornek GV, Valencak JB, Oberhuber G, Vorbeck F, Virgolini I, Scheithauer W: Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide. Am J Gastroenterol 1999, 94(1):278-279.
• [208]Siveke JT, Herberhold C, Folwaczny C: Complete regression of advanced HCC with long acting octreotide. Gut 2003, 52(10):1531.
• [209]Deming DA, Stella AL, Holen KD, Ku G, O'Reilly EM: A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma. Clin Adv Hematol Oncol 2005, 3(6):468-472. discussion 472–464
• [210]Borbath I, Lhommel R, Guiot Y, Coche E, Sempoux C: Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival. Acta Gastroenterol Belg 2012, 75(2):270-273.
• [211]Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Markidou S, Panagiotakos D, Chrysohoou C, Bazinis A, Paraskevas E: The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002, 49(47):1245-1250.
• [212]Gill ML, Atiq M, Sattar S, Khokhar N: Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature. J Pak Med Assoc 2005, 55(4):135-138.
• [213]Samonakis DN, Moschandreas J, Arnaoutis T, Skordilis P, Leontidis C, Vafiades I, Kouroumalis E: Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002, 9(4):903-907.
• [214]Plentz RR, Tillmann HL, Kubicka S, Bleck JS, Gebel M, Manns MP, Rudolph KL: Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage. J Gastroenterol Hepatol 2005, 20(9):1422-1428.
• [215]Schoniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Muller C: Octreotide treatment of patients with hepatocellular carcinoma–a retrospective single centre controlled study. J Exp Clin Cancer Res 2009, 28:142.
• [216]Slijkhuis WA, Stadheim L, Hassoun ZM, Nzeako UC, Kremers WK, Talwalkar JA, Gores GJ: Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol 2005, 39(4):333-338.
• [217]Pivonello R, Di Sarno A, Vitale G, Ferraioli G, Guerra E, de Stefano G, Lombardi G, Giorgio A, Hofland LJ, Colao A: Somatostatin analogs in the treatment of hepatocellular carcinoma: correlation between sst2 receptor expression and patients’survival [abstract]. Endocr Rev 2006, P3 613.
• [218]Del Prete S, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D'Agostino A, Faiola V, Addeo R: Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemother Pharmacol 2010, 66(5):837-844.
• [219]Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, Abbruzzese A, Stiuso P: Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis 2011, 2:e150.
• [220]Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998, 42(3):442-447.
• [221]Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, Wong WM, Wong BC: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002, 36(3):687-691.
• [222]Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Oberg K: [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994, 131(6):577-581.
• [223]Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE, Group HS: Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007, 45(1):9-15.
• [224]Barbare JC, Bouche O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L: Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer 2009, 45(10):1788-1797.